Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Bariatric surgery reduces risk of all-cause death

28 Aug 2020

Patients who underwent bariatric surgery have considerably lower all-cause, cardiovascular, and cancer mortality, with the largest absolute effects seen in men and in those aged 55 years, according to a recent study.

“Mortality after bariatric surgery has been previously studied, but cohort selection bias, completeness of follow-up, and collection of confounders have limited the inference of results,” the authors said.

This population-based matched cohort study assessed the association between bariatric surgery and all-cause mortality in 13,679 patients who went through the procedure from January 2010 to December 2016 and in 13,679 matched nonsurgical individuals in Ontario, Canada.

The overall mortality rate after a median follow-up of 4.9 years was lower in the surgery group compared with the nonsurgery group (1.4 percent vs 2.5 percent), with a lower adjusted hazard ratio (HR) of overall all-cause mortality (HR, 0.68, 95 percent CI, 0.57–0.81).

Patients aged 55 years had a 3.3-percent (95 percent CI, 2.3–4.3 percent) absolute risk reduction, with a lower HR of mortality in the surgery group (HR, 0.53, 95 percent CI, 0.41–0.69). Although the relative effects observed were comparable across sex, men showed greater association in absolute terms.

In addition, surgery resulted in reduced cardiovascular mortality (HR, 0.53, 95 percent CI, 0.34–0.84) and lower cancer mortality (HR, 0.54, 95 percent CI, 0.36–0.80).

This study, however, was limited by its observation design.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.